Valneva SE (EPA:VLA)
France · Delayed Price · Currency is EUR | Market Cap | 416.14M -10.3% |
| Revenue (ttm) | 174.66M +3.0% |
| Net Income | -115.19M |
| EPS | -0.68 |
| Shares Out | 173.75M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 556,416 |
| Average Volume | 1,201,968 |
| Open | 2.370 |
| Previous Close | 2.395 |
| Day's Range | 2.322 - 2.399 |
| 52-Week Range | 2.323 - 5.415 |
| Beta | 1.53 |
| RSI | 24.90 |
| Earnings Date | May 7, 2026 |
About Valneva SE
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease ca... [Read more]
Financial Performance
In 2025, Valneva SE's revenue was 174.66 million, an increase of 3.00% compared to the previous year's 169.58 million. Losses were -115.19 million, 840.6% more than in 2024.
Financial StatementsNews
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Valneva SE – VALN
NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Valneva SE (“Valneva” or the “Company”) (NASDAQ: VALN). Such investors are advised to conta...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN
NEW YORK, April 16, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Valneva SE ("Valneva" or the "Company") (NASDAQ: VALN). Such investors are advised to contact D...
Declaration of shares and voting rights of Valneva SE – March 2026
VALNEVA Declaration of shares and voting rights March 31, 2026 __________________________________________________________________________________________ Company name: VALNEVARegistered office: Îlot S...
Valneva to Participate in Multiple Events at the 26th World Vaccine Congress in Washington DC
Lyon (France), March 26, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced its participation in the upcoming 26th World Vaccine Congress, which will t...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Valneva SE – VALN
NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Valneva SE (“Valneva” or the “Company”) (NASDAQ: VALN). Such investors are advised to conta...
Valneva (VALN) Maintains Buy Rating Despite Vaccine Trial Challenges
Valneva (VALN) Maintains Buy Rating Despite Vaccine Trial Challenges
An experimental Lyme disease vaccine from Pfizer and Valneva was effective at preventing the tick-borne disease in a new clinical trial but the findings aren't conclusive
The drugmaker is seeking regulatory review for the first new shot to combat the disease in decades.
Lyme disease vaccine 70 percent effective: Pfizer
A Lyme disease vaccine produced by Pfizer and Valneva was deemed 70 percent effective by the companies after they reviewed the results from a phase 3 trial. If approved by regulators, it would be the ...
Pfizer and Valneva's Lyme disease vaccine shows 70% efficacy in clinical trial
Pfizer and Valneva's Lyme disease vaccine has shown promising results in clinical trials, paving the way for regulatory approval despite setbacks due to fewer cases than expected, according to the com...
Valneva-Pfizer Lyme Shot Stumbles Yet Keeps Regulatory Path Alive
The Phase 3 VALOR trial results showed that fewer Lyme disease cases were accrued than anticipated, and the primary endpoint was not met in the first analysis.
Pfizer to seek FDA approval for Lyme disease vaccine candidate despite trial miss
Pfizer said it will seek regulatory approval for a Lyme disease vaccine candidate despite failing a late-stage trial. Pfizer said not enough people contracted Lyme disease to be confident in the resul...
Valneva Plunges As Lyme Vaccine Misses Key Goal In Phase 3 Trial; Shows More Than 70% Efficacy
(RTTNews) - Valneva SE (VALN) saw its stock drop sharply, even as the company and partner Pfizer announced that their Lyme disease vaccine candidate demonstrated more than 70% efficacy in a large Phas...
Valneva, Venture Global And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining around 1,000 points on Monday. Shares of Valneva SE (NASDAQ: VALN) fell sharply in pre- market trading . Pfizer (NYSE: PFE) ...
Pfizer: Lyme Disease Vaccine Candidate Shows Strong Efficacy In Phase 3 VALOR Trial
(RTTNews) - Pfizer (PFE) and Valneva SE (VALN) announced topline results from the Phase 3 VALOR Vaccine Against Lyme for Outdoor Recreationists trial of its investigational 6-valent OspA-based Lyme di...
Pfizer and French partner to seek approval for Lyme disease vaccine after late-stage trial
Pharmaceutical giant Pfizer and French partner Valneva on Monday said they planned to seek regulatory approval for a Lyme disease vaccine after a late-stage trial.
Pfizer, Valneva Report Strong Efficacy Data From Lyme Vaccine Trial
Pharmaceutical giant Pfizer and French vaccine maker Valneva reported positive topline results from their phase three study of a vaccine candidate for Lyme disease.
Pfizer-Valneva Lyme disease shot shows more than 70% efficacy in late-stage trial
U.S. drugmaker Pfizer and France's Valneva said on Monday their experimental Lyme disease vaccine showed more than 70% efficacy in a late-stage trial.
Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial
NEW YORK & LYON, France--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced topline results from the Phase 3 VALOR “Vaccine Against Lyme for Ou...
Elaris Secures Exclusive Global License from Valneva for C. difficile Vaccine Program
VIENNA, Austria, March 18, 2026 /PRNewswire/ -- Elaris FlexCo ("Elaris"), an Austrian biotechnology company developing vaccines against serious bacterial infections, today announced an exclusive globa...
Valneva Reports Full Year 2025 Audited Consolidated Financial Results
Lyon (France), March 18, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported its audited consolidated financial results for the year ended December 31, 2...
Valneva to Report Full Year 2025 Consolidated Financial Results on March 18, 2026
Lyon (France), March 9 , 202 6 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it will report its full year 2025 financial results on Wednesday, M...
VALNEVA Declaration of shares and voting rights: February 28, 2026
VALNEVA Declaration of shares and voting rights February 28, 2026 __________________________________________________________________________________________ Company name: VALNEVARegistered office: Îlo...
Valneva to Participate in Upcoming Investor Conferences
Lyon (France), March 2, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced its senior management will present and meet with investors at upcoming inves...
Valneva Reports Preliminary Unaudited 2025 Revenue and Cash and Provides 2026 Outlook
Lyon (France), February 19, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) a specialty vaccine company, today reported its preliminary unaudited full-year 2025 revenue and cash results1 and pro...
Valneva Provides Update on Recommendations for Use of IXCHIQ® in the United Kingdom
Lyon (France), February 13, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that following a review of the benefits and risks of the Company's sing...